Remdesivir treatment and clinical outcome in non-severe hospitalized COVID-19 patients: a propensity score matching multicenter Italian hospital experience.
In: European Journal of Clinical Pharmacology, Jg. 79 (2023-07-01), Heft 7, S. 967-974
Online
academicJournal
Zugriff:
Introduction: Remdesivir exerts positive effects on clinical improvement, even though it seems not to affect mortality among COVID-19 patients; moreover, it was associated with the occurence of marked bradycardia. Methods: We retrospectively evaluated 989 consecutive patients with non-severe COVID-19 (SpO 2 ≥ 94% on room air) admitted from October 2020 to July 2021 at five Italian hospitals. Propensity score matching allowed to obtain a comparable control group. Primary endpoints were bradycardia onset (heart rate < 50 bpm), acute respiratory distress syndrome (ARDS) in need of intubation and mortality. Results: A total of 200 patients (20.2%) received remdesivir, while 789 standard of care (79.8%). In the matched cohorts, severe ARDS in need of intubation was experienced by 70 patients (17.5%), significantly higher in the control group (68% vs. 31%; p < 0.0001). Conversely, bradycardia, experienced by 53 patients (12%), was significantly higher in the remdesivir subgroup (20% vs. 1.1%; p < 0.0001). During follow-up, all-cause mortality was 15% (N = 62), significantly higher in the control group (76% vs. 24%; log-rank p < 0.0001), as shown at the Kaplan–Meier (KM) analysis. KM furthermore showed a significantly higher risk of severe ARDS in need of intubation among controls (log-rank p < 0.001), while an increased risk of bradycardia onset in the remdesivir group (log-rank p < 0.001). Multivariable logistic regression showed a protective role of remdesivir for both ARDS in need of intubation (OR 0.50, 95%CI 0.29–0.85; p = 0.01) and mortality (OR 0.18, 95%CI 0.09–0.39; p < 0.0001). Conclusions: Remdesivir treatment emerged as associated with reduced risk of severe acute respiratory distress syndrome in need of intubation and mortality. Remdesivir-induced bradycardia was not associated with worse outcome. [ABSTRACT FROM AUTHOR]
Copyright of European Journal of Clinical Pharmacology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Remdesivir treatment and clinical outcome in non-severe hospitalized COVID-19 patients: a propensity score matching multicenter Italian hospital experience.
|
---|---|
Autor/in / Beteiligte Person: | Attena, Emilio ; Caturano, Alfredo ; Annunziata, Anna ; Maraolo, Alberto Enrico ; De Rosa, Annunziata ; Fusco, Francesco Maria ; Halasz, Geza ; Dall'Ospedale, Valeria ; Conte, Maddalena ; Parisi, Valentina ; Galiero, Raffaele ; Sasso, Ferdinando Carlo ; Fiorentino, Giuseppe ; Russo, Vincenzo |
Link: | |
Zeitschrift: | European Journal of Clinical Pharmacology, Jg. 79 (2023-07-01), Heft 7, S. 967-974 |
Veröffentlichung: | 2023 |
Medientyp: | academicJournal |
ISSN: | 0031-6970 (print) |
DOI: | 10.1007/s00228-023-03499-z |
Schlagwort: |
|
Sonstiges: |
|